EGFR and non-small cell lung carcinoma: It comes that the therapy using EGFR-TKIs and angiogenesis inhibitors, contrasts with EGFR-TKIs only therapy, prolonged the PFS of advanced NSCLC patients carrying 21L858 mutation [HR:0.64 (95%CI: 0.56~0.72, P<0.00001)] (Fig. 4).